NO20060444L - N-{4'-substituerte piperazin-1-sulfonylmetylalkyl}-N-hydroksyformamid forbindelser som metallproteinaseinhibitorer - Google Patents

N-{4'-substituerte piperazin-1-sulfonylmetylalkyl}-N-hydroksyformamid forbindelser som metallproteinaseinhibitorer

Info

Publication number
NO20060444L
NO20060444L NO20060444A NO20060444A NO20060444L NO 20060444 L NO20060444 L NO 20060444L NO 20060444 A NO20060444 A NO 20060444A NO 20060444 A NO20060444 A NO 20060444A NO 20060444 L NO20060444 L NO 20060444L
Authority
NO
Norway
Prior art keywords
alkyl
compounds
ring
aryl
sulfonylmethylalkyl
Prior art date
Application number
NO20060444A
Other languages
English (en)
Norwegian (no)
Inventor
David Waterson
Maurice Raymond Verscho Finlay
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27656653&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20060444(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20060444L publication Critical patent/NO20060444L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20060444A 2003-06-27 2006-01-27 N-{4'-substituerte piperazin-1-sulfonylmetylalkyl}-N-hydroksyformamid forbindelser som metallproteinaseinhibitorer NO20060444L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0301922A SE0301922D0 (sv) 2003-06-27 2003-06-27 Novel compounds
PCT/GB2004/002702 WO2005000822A1 (en) 2003-06-27 2004-06-23 N-{‘4-substituted piperazine-1-sulfonylmethyl!alkyl}-n-hydroxyfomamide compounds as metalloproteinase inhibitors

Publications (1)

Publication Number Publication Date
NO20060444L true NO20060444L (no) 2006-03-22

Family

ID=27656653

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060444A NO20060444L (no) 2003-06-27 2006-01-27 N-{4'-substituerte piperazin-1-sulfonylmetylalkyl}-N-hydroksyformamid forbindelser som metallproteinaseinhibitorer

Country Status (33)

Country Link
US (1) US7485644B2 (pl)
EP (1) EP1644340B1 (pl)
JP (1) JP4701167B2 (pl)
KR (1) KR20060026440A (pl)
CN (2) CN102229589A (pl)
AR (1) AR044931A1 (pl)
AT (1) ATE414063T1 (pl)
AU (1) AU2004251104B2 (pl)
BR (1) BRPI0411929A (pl)
CA (1) CA2529468A1 (pl)
CO (1) CO5650254A2 (pl)
CY (1) CY1108757T1 (pl)
DE (1) DE602004017733D1 (pl)
DK (1) DK1644340T3 (pl)
ES (1) ES2315675T3 (pl)
HR (1) HRP20090009T3 (pl)
IL (1) IL172615A0 (pl)
IS (1) IS8257A (pl)
MX (1) MXPA05013460A (pl)
MY (1) MY138680A (pl)
NO (1) NO20060444L (pl)
NZ (1) NZ544208A (pl)
PL (1) PL1644340T3 (pl)
PT (1) PT1644340E (pl)
RU (1) RU2351595C2 (pl)
SA (1) SA04250224B1 (pl)
SE (1) SE0301922D0 (pl)
SI (1) SI1644340T1 (pl)
TW (1) TW200524898A (pl)
UA (1) UA81491C2 (pl)
UY (1) UY28387A1 (pl)
WO (1) WO2005000822A1 (pl)
ZA (1) ZA200510458B (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0427403D0 (en) * 2004-12-15 2005-01-19 Astrazeneca Ab Novel compounds I
CA2623879C (en) * 2005-10-26 2014-03-25 Laboratoires Serono S.A. Sulfonamide derivatives and use thereof for the modulation of metalloproteinases
CN101007794B (zh) * 2006-01-26 2010-09-01 中国科学院上海药物研究所 N,n'-二取代哌嗪类衍生物及其制备方法、药物组合物和用途
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
PT2597084T (pt) * 2010-07-08 2016-08-12 Kaken Pharma Co Ltd Derivado de n-hidroxiformamida e medicamento contendo o mesmo

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002501943A (ja) * 1998-01-30 2002-01-22 ダーウィン・ディスカバリー・リミテッド ヒドロキサム酸およびカルボン酸誘導体
GB9919776D0 (en) * 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
JP2003501414A (ja) * 1999-06-04 2003-01-14 アストラゼネカ・アクチエボラーグ メタロプロテイナーゼの阻害剤
EP1261590B1 (en) 2000-02-21 2012-04-11 AstraZeneca AB Piperidine- and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases
GB0119472D0 (en) * 2001-08-09 2001-10-03 Astrazeneca Ab Compounds
AU2003221786A1 (en) * 2002-04-25 2003-11-10 Pharmacia Corporation Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
AU2004249496A1 (en) * 2003-06-19 2004-12-29 Ucb Pharma S.A. Hydroxamate sulfonamides as CD23 shedding inhibitors

Also Published As

Publication number Publication date
IL172615A0 (en) 2006-04-10
SI1644340T1 (sl) 2009-02-28
PL1644340T3 (pl) 2009-04-30
UY28387A1 (es) 2005-01-31
EP1644340B1 (en) 2008-11-12
HK1086835A1 (en) 2006-09-29
AU2004251104A1 (en) 2005-01-06
ATE414063T1 (de) 2008-11-15
CO5650254A2 (es) 2006-06-30
DK1644340T3 (da) 2009-02-02
CN1812974A (zh) 2006-08-02
AR044931A1 (es) 2005-10-12
CA2529468A1 (en) 2005-01-06
EP1644340A1 (en) 2006-04-12
CY1108757T1 (el) 2014-04-09
ZA200510458B (en) 2007-03-28
HRP20090009T3 (en) 2009-02-28
PT1644340E (pt) 2009-01-02
RU2351595C2 (ru) 2009-04-10
US7485644B2 (en) 2009-02-03
IS8257A (is) 2006-01-23
ES2315675T3 (es) 2009-04-01
WO2005000822A1 (en) 2005-01-06
MXPA05013460A (es) 2006-03-09
US20070197542A1 (en) 2007-08-23
KR20060026440A (ko) 2006-03-23
SE0301922D0 (sv) 2003-06-27
JP2007516164A (ja) 2007-06-21
JP4701167B2 (ja) 2011-06-15
UA81491C2 (en) 2008-01-10
RU2005141058A (ru) 2006-07-27
BRPI0411929A (pt) 2006-08-15
NZ544208A (en) 2009-02-28
SA04250224B1 (ar) 2009-05-31
CN1812974B (zh) 2011-06-29
DE602004017733D1 (de) 2008-12-24
TW200524898A (en) 2005-08-01
MY138680A (en) 2009-07-31
AU2004251104B2 (en) 2008-05-08
CN102229589A (zh) 2011-11-02

Similar Documents

Publication Publication Date Title
NO20062517L (no) 2-cyanopyrrolidinkarboksamidforbindelse
MX2023003410A (es) Forma polimorfica cristalina a de un inhibidor de jak y metodos para su preparacion.
NO20080030L (no) Nye mandelsyre-derivater og anvendelse derav som trombininhibitorer
NO20054195L (no) Isoksazolforbindelser som inhibitorer for varmesjokkproteiner
NO20055568L (no) Substituerte 1,4-diazepiner og anvendelser derav
MXPA04001016A (es) Derivados de sulfonamida como inhibidores de la gamma secretasa.
TW200635585A (en) Monocyclic substituted methanones
MXPA05007496A (es) Tienopirimidindionas y su uso en la modulacion de enfermedades autoinmunes.
NO20074303L (no) 7-{4-[2-(2,6-diklor-4-metylfenoksy)etoksy]fenyl}-3,9-diazabisyklo-[3.3.1]non-6-en-6-karboksylsyresyklopropyl-(2,3-dimetylbenzyl)amid som renininhibitor til behandling av hypertensjon
NO20054264L (no) Ikke-Nukleoside Revers Transkriptase-Inhibitorer I for behandling av HIV-medierte sydommer
EA200401519A1 (ru) N- ациламинобензольные производные в качестве селективных ингибиторов моноаминооксидазы b
PT1590321E (pt) Derivados de arilalquilcarbamatos, sua preparaã†o e sua aplicaã†o em terapia
EA200500717A1 (ru) Новые соединения имидазопиридина, способ их получения и фармацевтические композиции, которые их содержат
NO20032731L (no) Fremgangsmåte for fremstilling av sulfonamid-substituerte imidazotriazinoner
NO20060444L (no) N-{4'-substituerte piperazin-1-sulfonylmetylalkyl}-N-hydroksyformamid forbindelser som metallproteinaseinhibitorer
NO20051047L (no) Fremgangsmate og mellomprodukter for fremstilling av tienopyrrolderivater
BR0205683A (pt) Processo para a preparação de derivados de piperazina, e, mesilato de um composto
NO20063330L (no) Amidderivater med en syklopropylaminokarbonylsubstituent som er nyttige som cytokininhibitorer
NO176176B (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive arylsulfonamider
NO20082226L (no) 6-heteroarylpyridoindolonderivater, deres fremstilling og terapeutisk anvendelse derav
ATE442354T1 (de) Pyrrolidinderivate als oxytocin antagonisten
Biasotti et al. Synthesis of photoactivable inhibitors of osteoclast vacuolar ATPase
DK169517B1 (da) [Aryl](3-pyridinyl)methanon,oximderivater samt fremgangsmåde til fremstilling deraf
NO20000373D0 (no) Nye cyano-indol serotinin-reopptaks-inhibitorforbindelser, fremgangsmåte for deres fremstilling og farmasoeytiske sammensetninger inneholdende dem
NO20063111L (no) Fremgangsmate for fremstilling av tiazolpyrimidiner

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application